Related Experiment Videos
Extracorporeal methods in lipid reduction pursuant to improvement in risk factors associated with atherosclerosis
1Lobdell Development and Design, Denver, Colorado.
Insights
This study reviews extracorporeal lipid-lowering methods for atherosclerosis risk factors like high cholesterol and lipoprotein(a) [Lp(a)]. It estimates the number of patients who could benefit from these apheresis procedures.
Area of Science:
- Cardiovascular Medicine
- Lipid Metabolism
- Medical Technology
Background:
- Atherosclerosis is a primary cause of mortality in the US.
- Elevated low-density lipoprotein and lipoprotein(a) [Lp(a)], with low high-density lipoprotein, are key risk factors for atherosclerotic coronary heart disease.
Purpose of the Study:
- To review extracorporeal methods for managing dyslipidemia in atherosclerosis.
- To analyze the impact of apheresis on lipoprotein(a) [Lp(a)] using kinetic modeling.
- To estimate the patient population that could benefit from extracorporeal lipid reduction therapies.
Main Methods:
- Literature review of extracorporeal lipid-lowering techniques.
- Application of kinetic modeling to assess lipoprotein(a) [Lp(a)] apheresis.
- Estimation of patient numbers for lipid-lowering interventions.
Main Results:
- Extracorporeal methods offer a means to modify key atherosclerosis risk factors.
- Kinetic modeling provides insights into the effectiveness of apheresis for lipoprotein(a) [Lp(a)] reduction.
- A calculated estimate of potential beneficiaries for extracorporeal lipid lowering is presented.
Conclusions:
- Extracorporeal lipid-lowering strategies, including apheresis, are important for managing atherosclerosis.
- Further research and application of kinetic modeling can optimize apheresis therapy for lipoprotein(a) [Lp(a)].
- A significant patient cohort may benefit from these advanced lipid management techniques.
Abstract:
Atherosclerosis is the leading cause of death in the United States. Elevated plasma levels of low-density lipoprotein and lipoprotein(a) [Lp(a)] and subnormal levels of high density lipoprotein are risk factors in atherosclerotic coronary heart disease. Extracorporeal methods of affecting these risk factors are reviewed. The limited information on the effects of apheresis procedures on Lp(a) is discussed and extended from a kinetic modeling approach. An estimate, made of the number of patients who could be expected to benefit from extracorporeal lipid lowering, is presented.